IDE Activateurs

Les activateurs IDE courants comprennent, entre autres, l'A-769662 CAS 844499-71-4, l'Honokiol CAS 35354-74-6, le 2-Deoxy-D-glucose CAS 154-17-6, la Berbérine CAS 2086-83-1 et le Dichlorhydrate de Dorsomorphine CAS 1219168-18-9.

IDE activators are a diverse group of chemicals carefully selected to modulate the activity of IDE, a crucial enzyme involved in the degradation of Aβ peptides. A769662, an AMPK activator, indirectly activates IDE by promoting AMPK phosphorylation. This activation enhances IDE expression, facilitating its role in Aβ peptide clearance. Similarly, honokiol activates IDE by modulating the Akt pathway, promoting Akt activation and increasing IDE expression, thus facilitating Aβ peptide degradation. 2-deoxy-D-glucose, a glycolytic inhibitor, indirectly activates IDE by disrupting glucose metabolism. This metabolic change increases IDE expression, favoring its role in Aβ peptide clearance. Berberine activates IDE by modulating the AMPK pathway, resulting in increased IDE expression and facilitating Aβ peptide degradation. Dorsomorphine, an AMPK inhibitor, indirectly activates IDE by blocking AMPK phosphorylation, promoting IDE expression and facilitating Aβ peptide clearance.

Resveratrol activates IDE by modulating the SIRT1 pathway, resulting in increased IDE expression and facilitating Aβ peptide degradation. Metformin, another AMPK activator, increases IDE expression by promoting AMPK phosphorylation, facilitating Aβ peptide clearance. Curcumin activates IDE by modulating the Akt pathway, resulting in increased IDE expression and promoting Aβ peptide degradation. D-pinitol indirectly activates IDE by promoting the PI3K/Akt pathway, increasing IDE expression and facilitating Aβ peptide clearance. Quercetin activates IDE by modulating the Akt pathway, resulting in increased IDE expression and facilitating Aβ peptide degradation. PF-06409577, an AMPK activator, increases IDE expression by promoting AMPK phosphorylation, facilitating Aβ peptide clearance. Compound C, an AMPK inhibitor, indirectly activates IDE by blocking AMPK phosphorylation, resulting in increased IDE expression and promoting Aβ peptide clearance. In conclusion, IDE activators offer a nuanced approach to enhancing IDE activity, either directly through activation of AMPK or Akt pathways, or indirectly through modulation of metabolic and signalling pathways. These chemicals are invaluable tools for researchers seeking to understand and intervene in the processes associated with Aβ peptide accumulation, leading to a better understanding of the complex mechanisms underlying neurodegenerative disorders.